You are here

  • Home
  • Archive
  • Volume 57, Issue 1
  • Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate

Article Text

Article menu
Download PDFPDF
Concise reports
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate
  1. Nicolino Rupertoa,
  2. Angelo Ravellib,
  3. Fernanda Falcinic,
  4. Loredana Lepored,
  5. Rosetta De Sanctise,
  6. Francesco Zulianf,
  7. Antonella Buoncompagnig,
  8. Maria Luisa Sardellah,
  9. Ciro Stranoi,
  10. Maria Alessioj,
  11. Stefania Violab,
  12. Alberto Martini for the Italian Pediatric Rheumatology Study Groupb
  1. aLaboratorio di Informatica Medica, IRCCS S Matteo, Pavia, Italy, bClinica Pediatrica, IRCCS S Matteo, Pavia, Italy, cClinica Pediatrica, Ospedale Meyer, Florence, Italy, dClinica Pediatrica, Istituto Burlo Garofalo, Trieste, Italy, eOspedale Bambin Gesù, Rome, Italy, fClinica Pediatrica, Padova, Italy, gII Divisione di Pediatria, Istituto Gaslini, Genova, Italy, hClinica Pediatrica, Università, Turin, Italy, iClinica Pediatrica, Naples, Italy, jII Divisione di Pediatria, Naples, Italy
  1. Dr A Martini, Clinica Pediatrica, Università di Pavia, IRCCS Policlinico S Matteo, P le Golgi 2, 27100 Pavia, Italy.

Abstract

OBJECTIVE To investigate the performance of the core set of outcome measures and the preliminary definition of improvement (PDI) in the assessment of response to methotrexate (MTX) treatment in children with juvenile chronic arthritis (JCA).

METHODS Data were obtained from an open label, non-controlled trial designed to investigate the efficacy of MTX in children with JCA. All patients had the core set of variables assessed at baseline and after six months of treatment. Variables in the core set are: (1) physician global assessment of disease activity; (2) parent or patient (if appropriate in age) global assessment of overall well being; (3) functional ability; (4) number of joints with active arthritis; (5) number of joints with limited range of motion; (6) erythrocyte sedimentation rate. The PDI specifies that to be classified as improved, a patient must show at least 30% improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30%.

RESULTS A total of 111 JCA patients were included in the study. According to the PDI, after six months of MTX treatment 73 patients (66%) were classified as improved and 38 (34%) as not improved. Among the core set variables, parent assessment detected the highest percentage of patients improved (72%) and functional assessment the lowest (37%).

CONCLUSION The PDI identifies about two thirds of patients with JCA treated with low dose MTX as improved. This proportion is similar to that expected to improve based upon a previous controlled study of low dose, oral MTX and provides preliminary evidence of the definition’s validity.

  • juvenile chronic arthritis
  • methotrexate
  • outcome measures
  • definition of improvement

https://doi.org/10.1136/ard.57.1.38

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text